Moloney Securities Asset Management LLC Purchases 6,930 Shares of GRAIL, Inc. (NASDAQ:GRAL)

Moloney Securities Asset Management LLC boosted its holdings in shares of GRAIL, Inc. (NASDAQ:GRAL - Free Report) by 22.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,266 shares of the company's stock after acquiring an additional 6,930 shares during the period. Moloney Securities Asset Management LLC owned approximately 0.11% of GRAIL worth $977,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sessa Capital IM L.P. acquired a new position in GRAIL during the fourth quarter worth approximately $53,550,000. Primecap Management Co. CA acquired a new position in GRAIL during the fourth quarter worth approximately $37,118,000. Baker BROS. Advisors LP acquired a new position in GRAIL during the fourth quarter worth approximately $29,098,000. Vanguard Group Inc. acquired a new position in GRAIL during the fourth quarter worth approximately $25,902,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in GRAIL during the fourth quarter worth approximately $18,209,000.

Insiders Place Their Bets

In other GRAIL news, CEO Robert P. Ragusa sold 94,035 shares of the company's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $33.93, for a total transaction of $3,190,607.55. Following the completion of the sale, the chief executive officer directly owned 734,627 shares in the company, valued at $24,925,894.11. This represents a 11.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Joshua J. Ofman sold 9,692 shares of the company's stock in a transaction on Monday, June 30th. The stock was sold at an average price of $52.00, for a total value of $503,984.00. Following the sale, the president owned 492,076 shares of the company's stock, valued at $25,587,952. The trade was a 1.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 532,890 shares of company stock valued at $23,556,972 over the last ninety days.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Canaccord Genuity Group upped their target price on GRAIL from $32.00 to $43.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. Morgan Stanley boosted their price target on GRAIL from $16.00 to $20.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 18th.

GRAIL Stock Performance

Shares of GRAL stock traded down $2.66 during trading on Friday, hitting $40.73. The company had a trading volume of 766,643 shares, compared to its average volume of 1,181,230. The firm has a market capitalization of $1.47 billion and a P/E ratio of -0.67. The stock's 50-day moving average price is $41.54 and its 200 day moving average price is $33.66. GRAIL, Inc. has a one year low of $12.33 and a one year high of $63.99.

GRAIL (NASDAQ:GRAL - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share for the quarter, topping the consensus estimate of ($4.03) by $0.93. GRAIL had a negative return on equity of 17.99% and a negative net margin of 1,464.53%. The firm had revenue of $31.84 million during the quarter, compared to analysts' expectations of $35.80 million. On average, research analysts anticipate that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.